Literature DB >> 17283137

Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.

Sarah E Golding1, Elizabeth Rosenberg, Steven Neill, Paul Dent, Lawrence F Povirk, Kristoffer Valerie.   

Abstract

The accurate joining of DNA double-strand breaks by homologous recombination repair (HRR) is critical to the long-term survival of the cell. The three major mitogen-activated protein (MAP) kinase (MAPK) signaling pathways, extracellular signal-regulated kinase (ERK), p38, and c-Jun-NH(2)-kinase (JNK), regulate cell growth, survival, and apoptosis. To determine the role of MAPK signaling in HRR, we used a human in vivo I-SceI-based repair system. First, we verified that this repair platform is amenable to pharmacologic manipulation and show that the ataxia telangiectasia mutated (ATM) kinase is critical for HRR. The ATM-specific inhibitor KU-55933 compromised HRR up to 90% in growth-arrested cells, whereas this effect was less pronounced in cycling cells. Then, using well-characterized MAPK small-molecule inhibitors, we show that ERK1/2 and JNK signaling are important positive regulators of HRR in growth-arrested cells. On the other hand, inhibition of the p38 MAPK pathway generated an almost 2-fold stimulation of HRR. When ERK1/2 signaling was stimulated by oncogenic RAF-1, an approximately 2-fold increase in HRR was observed. KU-55933 partly blocked radiation-induced ERK1/2 phosphorylation, suggesting that ATM regulates ERK1/2 signaling. Furthermore, inhibition of MAP/ERK kinase (MEK)/ERK signaling resulted in severely reduced levels of phosphorylated (S1981) ATM foci but not gamma-H2AX foci, and suppressed ATM phosphorylation levels >85% throughout the cell cycle. Collectively, these results show that MAPK signaling positively and negatively regulates HRR in human cells. More specifically, ATM-dependent signaling through the RAF/MEK/ERK pathway is critical for efficient HRR and for radiation-induced ATM activation, suggestive of a regulatory feedback loop between ERK and ATM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283137     DOI: 10.1158/0008-5472.CAN-06-2371

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.

Authors:  Yong Tang; Hossein A Hamed; Andrew Poklepovic; Yun Dai; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2012-05-17       Impact factor: 4.436

2.  Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.

Authors:  Annmarie Ramkissoon; Katherine E Chaney; David Milewski; Kyle B Williams; Rory L Williams; Kwangmin Choi; Adam Miller; Tanya V Kalin; Joseph G Pressey; Sara Szabo; Mohammad Azam; David A Largaespada; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2019-04-01       Impact factor: 12.531

3.  Regulation of protein synthesis by ionizing radiation.

Authors:  Steve Braunstein; Michelle L Badura; Qiaoran Xi; Silvia C Formenti; Robert J Schneider
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

4.  Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes.

Authors:  Yi-Chun Chen; E Scott Colvin; Katherine E Griffin; Bernhard F Maier; Patrick T Fueger
Journal:  Diabetologia       Date:  2014-07-04       Impact factor: 10.122

5.  Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.

Authors:  Seyedmehdi Shojaee; Rebecca Caeser; Maike Buchner; Eugene Park; Srividya Swaminathan; Christian Hurtz; Huimin Geng; Lai N Chan; Lars Klemm; Wolf-Karsten Hofmann; Yi Hua Qiu; Nianxiang Zhang; Kevin R Coombes; Elisabeth Paietta; Jeffery Molkentin; H Phillip Koeffler; Cheryl L Willman; Stephen P Hunger; Ari Melnick; Steven M Kornblau; Markus Müschen
Journal:  Cancer Cell       Date:  2015-06-11       Impact factor: 31.743

Review 6.  Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after.

Authors:  Jason M Beckta; Syed Farhan Ahmad; Hu Yang; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

Review 7.  Improving the efficacy of chemoradiation with targeted agents.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Discov       Date:  2014-02-18       Impact factor: 39.397

8.  The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.

Authors:  Younghyun Lee; Huizi Keiko Li; Aya Masaoka; Shigeaki Sunada; Hirokazu Hirakawa; Akira Fujimori; Jac A Nickoloff; Ryuichi Okayasu
Journal:  Radiother Oncol       Date:  2016-09-22       Impact factor: 6.280

9.  Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.

Authors:  Toshimitsu Tanaka; Anupama Munshi; Colin Brooks; Jenny Liu; Marvette L Hobbs; Raymond E Meyn
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

10.  Dynamic dependence on ATR and ATM for double-strand break repair in human embryonic stem cells and neural descendants.

Authors:  Bret R Adams; Sarah E Golding; Raj R Rao; Kristoffer Valerie
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.